The Drug That Turns Your Own Stress Hormones Against Cancer
Corcept Therapeutics just got FDA approval for the first drug that blocks cortisol from shielding tumors against chemotherapy. The approval came nearly four months early, and it could reshape treatment for the thousands of ovarian cancer patients who've run out of options.
Your body has a built-in panic button. When you're stressed, your adrenal glands flood your system with cortisol. It's supposed to help you survive. But in ovarian cancer, cortisol does something sinister: it helps the tumor survive instead.
For decades, nobody could figure out how to exploit that vulnerability without wrecking the rest of the body's hormone balance. Now, Corcept Therapeutics has done exactly that. And on March 25, 2026, the FDA agreed it works.
The Approval That Came Early
The FDA wasn't supposed to make its decision until July 11, 2026. That was the official PDUFA date (the deadline the agency sets for reviewing a drug application). Instead, the agency approved relacorilant, now branded Lifyorli, nearly four months ahead of schedule.
That kind of early action is unusual, and it tells you something about how the FDA viewed the data. The drug was approved in combination with nab-paclitaxel (a type of chemotherapy) for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who've already been through one to three prior treatments, including at least one round of bevacizumab.
This is the first FDA-approved selective glucocorticoid receptor antagonist for cancer. First in class. No biomarker required. That last part matters more than you'd think.
Why Platinum-Resistant Ovarian Cancer Is So Brutal
Let's back up. Ovarian cancer treatment usually starts with platinum-based chemotherapy. Most patients respond at first. Then, almost inevitably, the cancer stops responding. When it comes back within six months of finishing platinum treatment, doctors call it "platinum-resistant."
About 85% of ovarian cancer patients eventually become platinum-resistant. At that point, options get bleak fast.
The standard playbook is single-agent chemotherapy: drugs like pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine, or topotecan. Response rates? A dismal 10 to 15%. Median time before the cancer progresses again? Roughly . Median overall survival hovers around .
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
three to four months
12 months
Think of it like trying to put out a house fire with a garden hose. You're doing something, but the fire barely notices.
Until recently, the only meaningful addition was bevacizumab (an anti-angiogenesis drug), which helped somewhat but didn't change the survival math dramatically. Mirvetuximab soravtansine arrived for a biomarker-defined slice of patients (those with high folate receptor-alpha expression), but that leaves out a huge chunk of the population.
The field was desperate for something that could work broadly, without requiring a specific biomarker test to qualify.
Cortisol: The Tumor's Bodyguard
This is where the biology gets fascinating. Cortisol, the stress hormone, binds to glucocorticoid receptors (GR) inside cells. In normal life, this triggers a cascade of gene activity that helps you deal with stress. In a tumor cell, that same cascade does something different: it activates survival pathways that protect the cancer from chemotherapy.
Imagine a bouncer standing at the door of a nightclub, turning away the chemo drugs trying to get in and do their job. Cortisol, working through GR, is that bouncer.
This is especially problematic with taxane chemotherapies like paclitaxel. The very stress of receiving chemo triggers cortisol release, which then shields the tumor from the chemo. It's a vicious feedback loop: the treatment creates the conditions for its own failure.
Relacorilant was designed to block that loop. It's a selective GR antagonist, meaning it parks itself on the glucocorticoid receptor and prevents cortisol from activating it. The key word is "selective." Unlike mifepristone (an older GR blocker that also hits progesterone receptors), relacorilant only targets GR. No binding to progesterone, estrogen, mineralocorticoid, or androgen receptors. That selectivity avoids a laundry list of hormonal side effects that made earlier GR blockers impractical for chronic use.
The result: cortisol's bodyguard gets taken out, and the chemotherapy can actually do its job.
There's a bonus, too. Cortisol also suppresses your immune system's ability to fight cancer. By blocking GR, relacorilant appears to restore some of that immune function, including T-cell activation and cytokine production. It's pulling double duty.
The ROSELLA Trial: What the Numbers Say
The approval rested on the Phase 3 ROSELLA trial, which enrolled roughly 381 patients across 14 countries. The design was straightforward: relacorilant plus nab-paclitaxel versus nab-paclitaxel alone.
ROSELLA had two co-primary endpoints (the main things the trial needed to prove), and it hit both.
Progression-free survival (how long patients lived without their cancer getting worse) came in at 6.5 months in the combination arm versus 5.5 months with chemo alone. That translates to a 30% reduction in the risk of progression or death (hazard ratio of 0.70, p = 0.0076).
But the real headline was overall survival. Patients on the combination lived a median of 16.0 months compared to 11.9 months with chemo alone. That's a 35% reduction in the risk of death (HR 0.65, p = 0.0004).
To put that in perspective: in a disease where the standard of care gives you about a year, adding roughly four months of life is genuinely significant. And the clinical benefit rate at 24 weeks (the percentage of patients whose tumors shrank or at least stopped growing) was 51.1% versus 38.9% in the control arm.
Perhaps most importantly, the safety profile didn't meaningfully change. Side effects in the combination arm, things like low blood counts, fatigue, nausea, and diarrhea, were comparable in type and severity to nab-paclitaxel alone. The drug didn't pile extra toxicity onto an already tough regimen. Only 9% of patients permanently stopped treatment due to adverse reactions.
A Rollercoaster Year for Corcept
Corcept's path to this moment was anything but smooth. The company actually filed two separate applications for relacorilant, one for Cushing's syndrome (a condition caused by excess cortisol) and one for ovarian cancer.
The Cushing's filing hit a wall. On December 31, 2025, the FDA issued a Complete Response Letter, essentially a rejection. The agency had reportedly warned Corcept multiple times against submitting the application. UBS called the FDA's language "unusually strong." Corcept's stock cratered, falling about 50% on the news.
Analysts slashed their outlook. Truist Securities cut its price target from $135 to $50. The consensus probability of approval for the Cushing's syndrome indication dropped to just 44%, and forecast 2026 sales for relacorilant in Cushing's syndrome were chopped by 65%.
Then came the ovarian cancer approval in March 2026, and the story flipped. GlobalData's consensus forecast projects $3.38 billion in global sales by 2031 for the drug. Analyst price targets have climbed back to around $88, driven by the Lifyorli launch and the possibility of resubmitting the Cushing's application with additional data.
What Makes This Different From Everything Else
The platinum-resistant ovarian cancer landscape has been slowly evolving. Mirvetuximab soravtansine works well for FR-alpha-high patients. Pembrolizumab combinations from the KEYNOTE-B96 trial look promising for PD-L1-positive patients. But both of those require biomarker selection; if you don't have the right molecular profile, you're out of luck.
Relacorilant doesn't care about your biomarkers. No FRα test. No PD-L1 score. No BRCA status requirement. Subgroup analyses from ROSELLA showed benefits even in patients who had previously been treated with PARP inhibitors (a common earlier-line therapy), with hazard ratios of 0.60 and 0.56 for PFS in those groups.
That biomarker-agnostic profile could make Lifyorli the go-to option for the large swath of platinum-resistant patients who don't qualify for targeted therapies. And since it represents an entirely new mechanism of action, it slots into the treatment sequence without overlapping with existing drug classes.
Corcept has also filed a Marketing Authorization Application with the European Medicines Agency, setting up what could become a global franchise.
The Bigger Picture
Relacorilant's approval validates a hypothesis that researchers have been chasing for years: that cortisol signaling is a druggable target in cancer. The glucocorticoid receptor isn't just an endocrine curiosity; it's an active player in how tumors resist treatment and evade the immune system.
No other selective GR modulator is anywhere close to this stage of development in oncology. Corcept essentially owns the category. If the mechanism proves relevant in other tumor types (and there's preclinical reason to think it might), the company could be sitting on a platform, not just a single product.
For now, though, the story is about ovarian cancer patients who've run out of good options. For them, the idea that their own stress hormones have been helping their tumors survive, and that there's finally a drug to stop it, isn't just interesting science. It's a lifeline.
Deals & M&A
4 min read
The Virus No One Has a Drug For (and the €700M Bet to Change That)
Ipsen just dropped up to €700 million on a Swiss biotech's antibody that targets a virus most people have never heard of. The catch: it's the only thing in development for a condition that wrecks transplanted kidneys, and the Phase II results are messy enough to make things interesting.
